| __timestamp | Intra-Cellular Therapies, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 9086000000 |
| Thursday, January 1, 2015 | 87718074 | 8935000000 |
| Friday, January 1, 2016 | 93831530 | 9039000000 |
| Sunday, January 1, 2017 | 79419009 | 8972000000 |
| Monday, January 1, 2018 | 132166913 | 9074000000 |
| Tuesday, January 1, 2019 | 89124838 | 9402000000 |
| Wednesday, January 1, 2020 | 65782137 | 8980000000 |
| Friday, January 1, 2021 | 88845513 | 9540000000 |
| Saturday, January 1, 2022 | 134715000 | 9996000000 |
| Sunday, January 1, 2023 | 180142000 | 11371000000 |
| Monday, January 1, 2024 | 10022000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Novartis AG and Intra-Cellular Therapies, Inc. have demonstrated contrasting approaches to R&D investment. Novartis, a global leader, consistently allocates a significant portion of its resources to R&D, with expenditures peaking at approximately $11.4 billion in 2023. This represents a steady increase of around 25% from 2014. In contrast, Intra-Cellular Therapies, a smaller player, has shown a remarkable growth trajectory in its R&D spending, surging by over 750% from 2014 to 2023. This growth underscores the company's aggressive pursuit of innovation despite its smaller scale. Such investments are crucial as they drive the development of groundbreaking therapies, ultimately benefiting patients worldwide.
Research and Development Expenses Breakdown: Novartis AG vs Rhythm Pharmaceuticals, Inc.
R&D Spending Showdown: Novartis AG vs ACADIA Pharmaceuticals Inc.
R&D Insights: How Novartis AG and Iovance Biotherapeutics, Inc. Allocate Funds
Research and Development Investment: Zoetis Inc. vs Intra-Cellular Therapies, Inc.
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
Research and Development Investment: Genmab A/S vs Intra-Cellular Therapies, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Madrigal Pharmaceuticals, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Intra-Cellular Therapies, Inc. or Celldex Therapeutics, Inc.: Who Invests More in Innovation?